00:00
00:00
00:00

ValiRx - ValiSeek Clinical Development Update

Tue, 12 Dec 2017, 07:30am GMT

Dr Suzy Dilly, CEO of ValiSeek provides a positive update on the clinical progress of VAL401, the anti-cancer compound. The Company has released positive formal data pertaining to disease impact. The results demonstrate that the VAL401 treatment has a statistically significant improvement in Overall Survival for patients with non-small cell lung cancer compared to those receiving no treatment.

Suzanne Dilly
CEO, ValiSeek Limited